Once-daily gentamicin dosing in pediatric patients without cystic fibrosis

Pharmacotherapy

Volumn 30, Issue 3, 2010, Pages 248-253

  McDade, Erin J ^c   Wagner, Jeffrey L ^a   Moffett, Brady S ^a   Palazzi, Debra L ^a,b   Myers, Erin J ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Baylor College of Medicine ^*

Author keywords

Aminoglycosides; Gentamicin; Once daily dosing; Pediatrics

Indexed keywords

GENTAMICIN;

ABSCESS; ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; CELLULITIS; CHILD; CYSTIC FIBROSIS; DISTRIBUTION VOLUME; DRUG ELIMINATION; DRUG HALF LIFE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PANCREATITIS; PNEUMONIA; PRESCHOOL CHILD; SCHOOL CHILD; SEPSIS; SHUNT INFECTION; URINARY TRACT INFECTION;

ADOLESCENT; AGING; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; GENTAMICINS; HALF-LIFE; HUMANS; INFANT; MEDICAL RECORDS; METABOLIC CLEARANCE RATE; RETROSPECTIVE STUDIES;

EID: 77649212568     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.3.248     Document Type: Article

References (27)

1. Lacy MK, Nicolau DP, Nightingale CH, Quintilliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998;27:23-7.
2. Chambers HF. Antimicrobial agents: the aminoglycosides. In: Gilman AG, Hardman JG, Limbird LE, eds. The pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill; 2001:1219-38.
3. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987;31:1054-60.
4. MacKenzie FM, Gould IM. The postantibiotic effect. J Antimicrob Chemother 1993;32:519-37.
5. Zhanel G, Hoban D, Harding G. The postantibiotic effect: a review of in-vitro data. Ann Pharmacother 1991;25:153-63.
6. Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993;31(suppl D):149-58.
7. Vogelman B, Gudmundsson S, Tunidge J. In vivo postantibiotic effect in thigh infection in neutropenic mice. J Infect Dis 1998;157(2):287-98.
8. Daikos GL, Jackson GG, Lolans VT, Livermore DM. Adaptive resistance to aminoglycoside antibiotics from first-exposure down regulation. J Infect Dis 1990;162:414-20.
9. Gilleland LB, Lilleland HE, Gibson JA, Champlin FR. Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa. J Med Microbiol 1989;29:41-50.
10. Rogier F, Ducher M, Maurin M, et al. Aminoglycoside dosages and nephrotoxicity: quantitative relationships. Clin Pharmacokinet 2003;42(5):493-500.
11. Bertino JS, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993;167:173-9.
12. Maire PH, Corvaisier S, Rogier F, et al. Pharmacocinetique/ pharmacoduynamie clinique des antibiotiques. In: Precis de bacterioltie clinique. Paris, France: ESKA, 2003:715-31.
13. Rizzi MD, Hirose K. Aminoglycoside ototoxicity. Curr Opin Otolaryngol Head Neck Surg 2007;15:352-7.
14. Powell SH, Thompson WL, Luthe MA, et al. Once-daily vs. continuous aminoglycoside dosing in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983;147:918-32.
15. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991;35:399-405.
16. Nordstrom L, Ringberg H, Cronberg S, Tjernstrom O, Walder M. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J. Antimicrob Chemother 1990;25:159-73.
17. Peschere J, Bernard PA. Gentamicin ototoxicity can be avoided if a new therapeutic regimen is used. An experimental model [abstract]. In: programs and abstracts of the 24th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1984:93.
18. Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993;341:335-9.
19. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents and Chemother 1995;39:650-5.
20. Contopoulos-Ioannidis DG, Giotis ND, Baliasta DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 2004;114:e111-18.
21. Murphy JE. Aminoglycosides. In: Murphy JE, ed. Clinical Pharmacokinetics, 4th ed. Bethesda, MD: American Society of Health-System Pharmacists, 2008:27-60.
22. Duncan IB. Susceptibility of 1,500 isolates of Pseudomonas aeruginosa to gentamicin, carbenacillin, colisitin, and polymixin B. Antimicrob Agents Chemother 1974;5:9-15.
23. Carapetis JR, Jaquiery AL, Buttery JP, et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatr Infect Dis J 2001;20:240-6.
24. Schevchuk YM, Taylor DM. Aminoglycoside volume of distribution in pediatric patients. DICP Ann Pharmacother 1990;21:273-6.
25. Bates RD, Nahata MC, Jones JW, et al. Pharmacokinetics and safety of tobramcyin after once-daily administration in patients with cystic fibrosis. Chest 1997;112:1208-13.
26. Wallace AW, Jones M, Bertino JS. Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy 2002;22:1077-83.
27. Kim MJ, Bertino JS, Erb TA, et al. Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring and multiple-daily dosing. J Clin Pharmacol 2004;44:696-707. 253